Meaghan Rose Smith's appointment comes during a time of challenges for the biologics industry.
The Biosimilars Forum, a group formulated by major biosimilars companies to promote the use of biosimilars, has appointed Meaghan Rose Smith as its first executive director; she takes over at a time when soaring costs of biopharmaceuticals are under particular scrutiny and biosimilars face tough legal obstacles to gaining market traction.
Smith has Democratic connections and could be instrumental with the group’s efforts to promote biosimilars during the Biden administration. She was previously senior advisor and director of communications for HHS during the time the Obama administration worked on the Affordable Care Act (ACA), and previously she worked for Senator Brian Schatz, D-Hawaii, who currently sits on the Senate Committee on Appropriations.
“This is a critical time for the industry, and her extensive health care policy experience in both the private and public sector will be invaluable as we work to realize the significant cost-savings potential of biosimilars and face potential challenges to the BPCIA [Biologics Price Competition and Innovation Act],” said Juliana Reed, president of the Biosimilars Forum and vice president and global corporate affairs lead for Immunology, Inflammation, and Biosimilars at Pfizer.
The BPCIA, the pathway for biosimilar FDA approval, is a subsection of the ACA, which is under review for constitutional acceptability by the Supreme Court. Although a negative ruling striking down the ACA is not anticipated, it remains an outside possibility, according to legal experts.
“Biosimilars are key to lowering health care costs and can save the United States billions of dollars” said Smith. “Now more than ever, as we’re dealing with the devastating impact of the coronavirus pandemic and the Supreme Court considers the BPCIA with the ACA, the future of biosimilars is critical for patients and our country.”
Most recently, Smith headed health care strategies and coalition-building efforts at the public affairs firm SKDKnickerbocker in Washington, DC.
The Biosimilars Forum includes Biogen, Boehringer Ingelheim, Coherus BioSciences, Fresenius Kabi SwissBioSim, Merck and Co, Pfizer, Samsung Bioepis, Sandoz, and Teva.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient With MS Sues J&J Over ERISA Violation
February 14th 2024After a patient with multiple sclerosis (MS) was forced to pay exorbitant out-of-pocket costs for a brand name medication when she could’ve gotten a generic for way less, the patient filed a class action complaint against her employer, Johnson & Johnson (J&J), for violating the Employee Retirement Income Security Act of 1974 (ERISA).
Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars
January 11th 2024As Regeneron gears up for a legal battle with biosimilar competitors for its reference aflibercept, CareFirst files a lawsuit against Johnson & Johnson for restricting biosimilar ustekinumab competition; Celltrion and Accord BioPharma file with the FDA to approve their respective biosimilar candidates.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).